Hepatology Highlights

Omar Mousa, Harmeet Malhi, Robert E. Schwartz, Tasha B. Kulai, Hirsh D. Trivedi, Daryl T.Y. Lau, Nicole T. Shen, Robert S. Brown, Petra Hirsova, Xu Xu, Hayley T. Nicholls, Joseph F. Pisa, Zaid H. Tafesh, Brett E. Fortune, Vikas Gupta, Enis Kostallari, Nicholas Russo, Arun B. Jesudian – 27 February 2019

Hepatology Highlights

Omar Mousa, Harmeet Malhi, Robert E. Schwartz, Tasha B. Kulai, Hirsh D. Trivedi, Daryl T.Y. Lau, Nicole T. Shen, Robert S. Brown, Petra Hirsova, Xu Xu, Hayley T. Nicholls, Joseph F. Pisa, Zaid H. Tafesh, Brett E. Fortune, Vikas Gupta, Enis Kostallari, Nicholas Russo, Arun B. Jesudian – 27 February 2019

A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol‐Related Liver Disease

Nicole T. Shen, Annaheta Salajegheh, Robert S. Brown – 25 February 2019 – Alcohol‐related liver disease (ALD) is highly prevalent and appears to be increasingly reported with worsening mortality; thus, optimizing care in this patient population is imperative. This will require a multidisciplinary, multifaceted approach that includes recognizing alcohol use disorder (AUD) and existing treatments for AUD. We must also acknowledge the full spectrum of ALD clinically and histologically.

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes, James F. Trotter, Mustafa R. Bashir, Cynthia D. Guy, Rajarshi Banerjee, Mark J. Jaros, Sandra Owers, Bryan A. Baxter, Lei Ling, Alex M. DePaoli – 25 February 2019 – NGM282, an engineered fibroblast growth factor 19 analogue, rapidly and significantly reduced liver fat content in a multicenter, randomized, double‐blind, placebo‐controlled study in patients with biopsy‐confirmed nonalcoholic steatohepatitis (NASH). However, it is unclear whether these changes would be accompanied by histological improvement.

Subscribe to